/NWBO
NWBO Stock - Northwest Biotherapeutics, Inc.
Healthcare|BiotechnologyOTC
$0.25+0.00%
+$0.00 (+0.00%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.56
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.28
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NWBO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.25 – $0.25
TARGET (TP)$0.29
STOP LOSS$0.23
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.84
52W High$0.48
52W Low$0.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.38M | $1.93M | $1.68M | $1.00M | $1.29M |
| Gross Profit | $1.38M | $-25,798,000 | $135,000 | $-19,303,000 | $-32,346,000 |
| Gross Margin | 100.0% | -1335.3% | 8.0% | -1920.7% | -2505.5% |
| Operating Income | $-66,508,000 | $-55,508,000 | $-67,181,000 | $-52,702,000 | $-86,605,000 |
| Net Income | $-83,778,000 | $-62,599,000 | $-105,032,000 | $179.13M | $-529,821,000 |
| Net Margin | -6062.1% | -3240.1% | -6240.8% | 17823.5% | -41039.6% |
| EPS | $-0.07 | $-0.06 | $-0.10 | $0.21 | $-0.73 |
Company Overview
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NWBOBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-18.22
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | — | $-18.22 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.01 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.01 | — | — |
Q1 2025 | Mar 31, 2025 | — | $-0.02 | — | — |
Q4 2024 | Nov 12, 2024 | — | $-0.02 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-0.02 | — | — |
Q2 2024 | May 10, 2024 | — | $-0.02 | — | — |
Q1 2024 | Mar 5, 2024 | — | $-0.02 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.02 | — | — |
Q3 2023 | Aug 9, 2023 | — | $-0.01 | — | — |
Q2 2023 | May 10, 2023 | — | $-0.01 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-0.03 | — | — |
Q4 2022 | Nov 9, 2022 | — | $-0.03 | — | — |
Q3 2022 | Aug 9, 2022 | — | $-0.03 | — | — |
Q2 2022 | May 9, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 1, 2022 | — | $0.14 | — | — |
Q4 2021 | Nov 15, 2021 | — | $0.04 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.01 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NWBO
What is NWBO's current stock price?
Northwest Biotherapeutics, Inc. (NWBO) is currently trading at $0.25 per share. The stock has moved +0.00% today.
What is the analyst price target for NWBO?
No analyst price targets are currently available for this stock.
What sector is Northwest Biotherapeutics, Inc. in?
Northwest Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is NWBO's market cap?
Northwest Biotherapeutics, Inc. has a market capitalization of $0.39 billion, making it a small-cap company.
Does NWBO pay dividends?
No, Northwest Biotherapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVCTF
Avacta Group Plc
$1.11
Mkt Cap: $0.5B
CLVLY
Clinuvel Pharmaceuticals Limited
$8.38
Mkt Cap: $0.4B
CMVLF
Cellectis S.A.
$4.50
Mkt Cap: $0.3B
CYDY
CytoDyn Inc.
$0.28
Mkt Cap: $0.4B
FGHQF
Frontage Holdings Corporation
$0.15
Mkt Cap: $0.3B
HLOSF
Healios K.K.
$2.31
Mkt Cap: $0.2B
HNSBF
Hansa Biopharma AB (publ)
$2.91
Mkt Cap: $0.2B
MDCLF
MedinCell S.A.
$6.98
Mkt Cap: $0.2B
PRRUF
Immutep Limited
$0.27
Mkt Cap: $0.4B
PTCHF
PureTech Health plc
$1.55
Mkt Cap: $0.4B
Explore stocks similar to NWBO for comparison